clinical endpoint comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-07-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
Several questions remain unresolved. It is not yet known whether the compound reduces cardiovascular events or mortality, because outcome studies require long follow-up. The durability of weight reduction after treatment withdrawal is uncertain, and rebound has been observed with other incretin-based therapies. Long-term safety data covering several years are limited. Effects in adolescents, in pregnancy, and in people with significant kidney or liver impairment have not been characterized in published reports.
Randomized studies of retatrutide measure change in body weight as a percentage of baseline, along with absolute weight loss. Glycemic endpoints include hemoglobin A1c and fasting plasma glucose. Investigators also track blood pressure, lipid fractions, and liver fat content to characterize effects beyond weight alone. Trial designs typically use double-blind, placebo-controlled groups with periodic dose escalation, and they record adverse events throughout both treatment and follow-up periods.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
| Property | Value | Notes |
|---|---|---|
| Common matrix | Plasma or serum | Collected under controlled conditions |
| Primary method | Liquid chromatography–tandem mass spectrometry | Structural specificity |
| Alternative method | Immunoassay | Lower specificity, higher throughput |
| Reporting unit | ng/mL | Concentration in matrix |
| Key validation item | Selectivity | Interference from related peptides |
As a peptide, the compound is generally supplied as a lyophilized powder and stored frozen to slow degradation. Recommended conditions usually sit at minus twenty degrees Celsius or colder, shielded from light and moisture. Solutions are less stable than the dry powder and are often prepared fresh before analysis. Repeated freeze-thaw cycles can drive aggregation, so splitting stock material into small aliquots reduces handling stress and preserves sample integrity.
Quality control of research material relies on several complementary checks. Purity testing confirms the absence of truncated or oxidized peptide species, while water content and counterion analysis show how much mass comes from salts rather than the peptide itself. Sequence verification through tandem mass spectrometry ensures the correct amino acid chain. Because unregulated suppliers vary widely, independent verification of identity and purity is often necessary before a sample enters experiments.
Documentation plays a practical role in maintaining consistent results across laboratories. Certificates of analysis list purity, identity, and testing methods, and batch numbers allow comparisons between lots. Records of storage temperature and handling history help investigators interpret unexpected findings. When a sample behaves anomalously, reviewing that documentation often reveals whether the cause lies in the material or in the assay conditions.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
retatrutide 是一种人工合成的多肽，设计目标是同时作用于 GIP、GLP-1 与胰高血糖素三种受体。这种三重激动设计试图把多条代谢通路的调节整合进单一分子，而不是只依赖一种肠促胰素受体。分子骨架以天然肽序列为基础，经过非天然氨基酸替换和脂肪酸侧链修饰，以获得更长的作用时间。该方向属于多受体激动剂研究的一部分，与双重激动剂的工作并行推进。
三种受体在能量平衡中的分工并不相同：GLP-1 与 GIP 受体主要参与胰岛素分泌和食欲调节，胰高血糖素受体则与能量消耗及肝糖输出相关。同时激活三者可能产生叠加效应，也可能出现相互制约，具体结果取决于受体亲和力与组织分布。这种组合在理论上可能同时影响体重与血糖指标，但协同关系的细节仍处在研究阶段。
化学修饰延长了分子在体内的停留时间，使较低频次的给药安排成为可能。脂肪酸侧链通过与白蛋白结合延缓清除，非天然氨基酸则降低酶解速率。这些修饰同时改变分子的溶解性与稳定性，需要在制剂设计和储存条件中一并考虑。修饰引入的免疫原性风险也属于开发过程中需要评估的项目。
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
==== Legislature ==== The U.S. Congress is a bicameral legislature made up of the Senate and the House of Representatives. The Senate has 100 members—two residents from each state and elected by that state's voters for a six-year term. The House of Representatives has 435 voting members, elected for a two-year term by the constituency of the congressional district in which they reside. District boundaries are generally drawn by state legislatures or redistricting commissions under state law. Every U.S. congressional district must be as nearly equal in population as practicable; each sends one representative to Congress. Election years for senators are staggered so that only one-third of them will be up for election every two years. U.S. representatives are all up for election at the same time every two years. The U.S. Congress makes federal law, declares war, has the power of the purse, and has the power of impeachment. The Senate gives advice and consent to the ratification of treaties by a two-thirds vote of senators present. One of the foremost non-legislative functions of Congress is the power to investigate and oversee the executive branch. Congressional oversight is usually delegated to committees and is facilitated by Congress' power to issue subpoenas. Much of the work of Congress is performed by a collection of committees, each appointed for a specific purpose or function. Committee membership is by tradition and statute bipartisan, but all committees are chaired by a member of the majority party, who sets the committee agenda.
== Aircraft == Labcorp (ICAO: SKQ, call sign: SKYLAB) utilizes a fleet of 12 Pilatus PC-12 and a single Pilatus PC-24 aircraft on nightly runs from Burlington for use on the East Coast. Prior to the acquisition of PC-12 aircraft Labcorp utilized seven PA-31-350s.
== Research and career == In the 1980s, Mojsov moved to the Massachusetts General Hospital (MGH) where she was made head of a peptide synthesis facility. She arrived at MGH shortly after Joel Habener had cloned proglucagon by studying anglerfish found in Boston Harbor. Mojsov worked on the identification of glucagon-like peptide-1 (GLP-1), a hormone generated by the gut that triggers the release of insulin. The amino acid sequence of GLP-1 was similar to a gastric inhibitory peptide, an incretin. To try to identify whether a specific fragment of GLP-1 was an incretin, Mojsov synthesized an incretin-antibody and developed ways to track its presence. Specifically, Mojsov identified that a stretch of 31 amino acids in the GLP-1 was an incretin. Together with Gordon Weir at the Joslin Diabetes Center in Boston and Habener, Mojsov showed that physiologic concentration of 5 × 10−11 of lab-synthesized GLP-1 could trigger insulin. All other reports at that time were for much higher concentrations thus not meeting Cretuzfeld's requirement that an incretin "must stimulate insulin secretion in a glucose-dependent manner at physiological levels". In the 1990s, Mojsov returned to New York City, where she went back to Rockefeller University and the laboratory of Ralph M. Steinman (2011 Nobel Prize in Physiology or Medicine). In 1992, the group at Massachusetts General Hospital (MGH) using GLP-1 synthesized by Mojsov tested the GLP-1 in humans. Drugs that emulate the action of GLP-1 have been developed into treatments for obesity and diabetes by Novo Nordisk and Eli Lilly.
A tooth from what is now documented as a Tyrannosaurus rex was found in July 1874 upon South Table Mountain (Colorado) by Jarvis Hall student Peter T. Dotson under the auspices of Arthur Lakes near Golden, Colorado, in sediments belonging to the Denver Formation. In the early 1890s, John Bell Hatcher collected postcranial elements in eastern Wyoming. The fossils were believed to be from the large species Ornithomimus grandis (now Deinodon) but are now considered T. rex remains. In 1892, Edward Drinker Cope found two vertebral fragments of a large dinosaur. Cope believed the fragments belonged to an "agathaumid" (ceratopsid) dinosaur, and named them Manospondylus gigas, meaning "giant porous vertebra", in reference to the numerous openings for blood vessels he found in the bone. The M. gigas remains were, in 1907, identified by Hatcher as those of a theropod rather than a ceratopsid. Henry Fairfield Osborn recognized the similarity between Manospondylus gigas and T. rex as early as 1917, by which time the second vertebra had been lost. Owing to the fragmentary nature of the Manospondylus vertebrae, Osborn did not synonymize the two genera, instead considering the older genus indeterminate. In June 2000, the Black Hills Institute found around 10% of a Tyrannosaurus skeleton (BHI 6248) at a site that might have been the original M. gigas locality. While Larson initially considered this specimen as the same animal as the M. gigas holotype and suggested that it would take priority over T. rex, other researchers including Christopher Brochu remained skeptical that the name T.
This reaction highlights a distinctive property of sulfur: its ability to catenate (bind to itself by formation of chains). Protonation of these polysulfide anions produces the polysulfanes, H2Sx where x = 2, 3, and 4. Ultimately, reduction of sulfur produces sulfide salts:
Sources: en.wikipedia.org
=== Manufacture === Merck KGaA currently relies on third-party manufacturers to supply the product candidate: On Baxter International for the manufacture of tecemotide, and on GlaxoSmithKline plc (GSK) for the manufacture of the adjuvant in tecemotide, monophosphoryl lipid A (MPL). As of 2013, there was a risk that if tecemotide were not approved by 2015, GSK could terminate its obligation to supply MPL. In this case, Oncothyreon would have had to retain the necessary licenses from GSK required to have the adjuvant MPL manufactured, but the transfer of the process to a third party would delay the development and commercialization of tecemotide.
=== The mathematics of substitution models === Stationary, neutral, independent, finite sites models (assuming a constant rate of evolution) have two parameters, π, an equilibrium vector of base (or character) frequencies and a rate matrix, Q, which describes the rate at which bases of one type change into bases of another type; element
== Computational methods == Molecular dynamics Protein structure prediction Protein sequence alignment (sequence comparison, including BLAST) Protein structural alignment Protein ontology (see gene ontology)
==== Clash jumpers ==== In 2007, the AFL Commission laid down the requirement that all clubs must produce an alternative jumper for use in matches where jumpers are considered to clash. From 2007 to 2011, the Essendon clash guernsey was the same design as its home guernsey, but with a substantially wider sash such that the guernsey was predominantly red rather than predominantly black. This was changed after 2011 when the AFL deemed that the wider sash did not provide sufficient contrast. From 2012 to 2016, Essendon's clash guernsey was predominantly grey, with a red sash fimbriated in black; the grey field contained, in small print, the names of all Essendon premiership players. Before the 2016 season, Essendon's changed their clash guernsey to a predominantly red one, featuring a red sash outlined in black. Similar to the grey jumper, the names of Essendon premiership players were also printed outside the sash. The 2025 season saw Essendon unveil a new away/clash guernsey, which is red with a black sash, a reverse of the home guernsey.
== Society and culture == People with noma and noma survivors may face stigma. Some think that noma is a contagious disease, so they avoid noma sufferers and survivors to avoid contracting it. Parents may hide afflicted children within the home because of social stigma, which can prevent them from getting treatment. Some also believe noma may be caused by witchcraft or a curse on the child's parents. Based on one 1997 estimate, roughly 770,000 people worldwide live with noma sequelae. However, "noma is a disease of shame," and children are sometimes hidden in isolation rather than being sent to receive treatment. In Nigeria, sufferers and their families may seek traditional medicine rather than go to a medical center. In a study of 7,185 noma sufferers across Nigeria, only 19% reported going to a hospital or medical center upon discovering a facial lesion. 47.6% took 1–3 weeks to visit a hospital; the rest took longer to visit a hospital. Children and other noma survivors in Africa are helped by a few international charitable organizations, such as Facing Africa, a UK registered charity that helps affected Ethiopians, and Swiss charity Winds of Hope. The Hilfsaktion Noma E.v is a non-governmental organization that has been involved in the management of Noma survivors for 30 years. They have a presence in 9 countries within the sub-Saharan Noma belt and have two fully funded clinics for the comprehensive management of Noma patients (one in Niger Republic and the other in Guinea Bissau).
Sources: en.wikipedia.org
== V == Valine Valinomycin Vanabins Vasopressin Verruculogen Vitamins (in general) Vitamin A (retinol) Vitamin B Vitamin B1 (thiamine) Vitamin B2 (riboflavin) Vitamin B3 (niacin or nicotinic acid) Vitamin B4 (adenine) Vitamin B5 (pantothenic acid) Vitamin B6 (pyridoxine or pyridoxamine) Vitamin B12 (cobalamin) Vitamin C (ascorbic acid) Vitamin D (calciferol) Vitamin E (tocopherol) Vitamin F Vitamin H (biotin) Vitamin K (naphthoquinone) Vitamin M (folic acid)
=== Research === Two live samples of variola major virus remain, one in the United States at the CDC in Atlanta, and one at the Vector Institute in Koltsovo, Russia. Research with the remaining virus samples is tightly controlled, and each research proposal must be approved by the WHO and the World Health Assembly (WHA). Most research on poxviruses is performed using the closely related Vaccinia virus as a model organism. Vaccinia virus, which is used to vaccinate for smallpox, is also under research as a viral vector for vaccines for unrelated diseases. The genome of variola major virus was first sequenced in its entirety in the 1990s. The complete coding sequence is publicly available online. The current reference sequence for variola major virus was sequenced from a strain that circulated in India in 1967. In addition, there are sequences for samples of other strains that were collected during the WHO eradication campaign. A genome browser for a complete database of annotated sequences of variola virus and other poxviruses is publicly available through the Viral Bioinformatics Resource Center.
Glucose from the bloodstream is taken up by GLUT4 from muscle cells (of the skeletal muscle and heart muscle) and fat cells. GLUT14 is expressed exclusively in testicles. Excess glucose is broken down and converted into fatty acids, which are stored as triglycerides. In the kidneys, glucose in the urine is absorbed via SGLT1 and SGLT2 in the apical cell membranes and transmitted via GLUT2 in the basolateral cell membranes. About 90% of kidney glucose reabsorption is via SGLT2 and about 3% via SGLT1.
==== Fugu as a food ==== Poisoning from tetrodotoxin is of particular public health concern in Japan, where fugu is a traditional delicacy. It is prepared and sold in special restaurants where trained and licensed chefs carefully remove the viscera to reduce the danger of poisoning. There is potential for misidentification and mislabelling, particularly of prepared, frozen fish products.
== Further reading == Chevance FV, Hughes KT (2 May 2017). "Case for the genetic code as a triplet of triplets". Proceedings of the National Academy of Sciences of the United States of America. 114 (18): 4745–4750. Bibcode:2017PNAS..114.4745C. doi:10.1073/pnas.1614896114. JSTOR 26481868. PMC 5422812. PMID 28416671. Dever TE (29 June 2012). "A New Start for Protein Synthesis". Science. 336 (6089). American Association for the Advancement of Science: 1645–1646. Bibcode:2012Sci...336.1645D. doi:10.1126/science.1224439. JSTOR 41585146. PMID 22745408. S2CID 44326947. Archived from the original on 8 June 2022. Retrieved 17 October 2020. Gardner RS, Wahba AJ, Basilio C, Miller RS, Lengyel P, Speyer JF (December 1962). "Synthetic polynucleotides and the amino acid code. VII". Proceedings of the National Academy of Sciences of the United States of America. 48 (12): 2087–2094. Bibcode:1962PNAS...48.2087G. doi:10.1073/pnas.48.12.2087. PMC 221128. PMID 13946552. Nakamoto T (March 2009). "Evolution and the universality of the mechanism of initiation of protein synthesis". Gene. 432 (1–2): 1–6. doi:10.1016/j.gene.2008.11.001. PMID 19056476. Wahba AJ, Gardner RS, Basilio C, Miller RS, Speyer JF, Lengyel P (January 1963). "Synthetic polynucleotides and the amino acid code. VIII". Proceedings of the National Academy of Sciences of the United States of America. 49 (1): 116–122. Bibcode:1963PNAS...49..116W. doi:10.1073/pnas.49.1.116. PMC 300638. PMID 13998282. Yanofsky C (9 March 2007). "Establishing the Triplet Nature of the Genetic Code". Cell. 128 (5): 815–818.
Sources: en.wikipedia.org
Trials measure percentage change in body weight, absolute weight loss, and glycemic markers such as hemoglobin A1c. They also record blood pressure, lipids, and liver fat. Adverse events are tracked throughout.
Mass spectrometry identifies molecules by mass-to-charge transitions, which reduces interference from related peptides. Immunoassays run faster but can cross-react. Structural confirmation usually requires the mass spectrometric approach.
Cardiovascular outcomes, long-term safety, and weight regain after stopping treatment are unresolved. These questions need years of follow-up data. Published evidence covers only limited treatment durations.
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.